Foamix Pharmaceuticals Ltd.. (FOMX) NASDAQ
$2.99 - (-)
Market Cap: $182.40M
As of 03/06/20 12:00 AM EST. Market closed.
Foamix Pharmaceuticals Ltd.. (FOMX)
NASDAQ
$2.99
- (-)
Market Cap: $182.40M
As of 03/06/20 12:00 AM EST. Market closed.
Foamix Pharmaceuticals Ltd. is a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The ... read more
Foamix Pharmaceuticals Ltd. is a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Domzalski David | CEO | Mar 02, 2020 | Option Exercise | $2.68 | 4,705 | 12,598 | 324,028 | Mar 03, 2020, 12:00 AM |
Wiley Matthew T. | Chief Commercial Officer | Mar 02, 2020 | Option Exercise | $2.68 | 1,993 | 5,336 | 114,074 | Mar 03, 2020, 12:00 AM |
Harsch Mutya | CLO and General Counsel | Mar 02, 2020 | Option Exercise | $2.68 | 1,761 | 4,715 | 98,232 | Mar 03, 2020, 12:00 AM |
Wiley Matthew T. | Chief Commercial Officer | Dec 31, 2019 | Option Exercise | $3.28 | 2,500 | 8,200 | 70,782 | Jan 03, 2020, 05:24 PM |
Stuart Iain | Chief Scientific Officer | Dec 31, 2019 | Option Exercise | $3.28 | 514 | 1,686 | 62,337 | Jan 03, 2020, 05:23 PM |
Harsch Mutya | CLO and General Counsel | Dec 31, 2019 | Option Exercise | $3.28 | 618 | 2,027 | 55,172 | Jan 03, 2020, 05:23 PM |
Domzalski David | CEO | Dec 31, 2019 | Option Exercise | $3.28 | 2,751 | 9,023 | 216,075 | Jan 03, 2020, 05:22 PM |
Domzalski David | CEO | Nov 29, 2019 | Option Exercise | $2.16 | 9,842 | 21,249 | 218,826 | Dec 03, 2019, 04:32 PM |
Wiley Matthew T. | Chief Commercial Officer | Nov 29, 2019 | Option Exercise | $2.16 | 9,842 | 21,249 | 73,282 | Dec 03, 2019, 04:31 PM |
Harsch Mutya | CLO and General Counsel | Nov 29, 2019 | Option Exercise | $2.16 | 4,284 | 9,249 | 55,790 | Dec 03, 2019, 04:30 PM |
Hirsch Stanley | Director | Nov 04, 2019 | Option Exercise | $0.62 | 32,500 | 20,150 | 182,500 | Nov 05, 2019, 04:32 PM |
Hirsch Stanley | Director | Oct 15, 2019 | Option Exercise | $0.62 | 90,000 | 55,800 | 150,000 | Oct 17, 2019, 04:11 PM |
Stuart Iain | Chief Scientific Officer | Sep 30, 2019 | Option Exercise | $3.07 | 673 | 2,066 | 62,851 | Oct 02, 2019, 04:20 PM |
Harsch Mutya | CLO and General Counsel | Sep 30, 2019 | Option Exercise | $3.07 | 463 | 1,421 | 51,506 | Oct 02, 2019, 04:19 PM |
Domzalski David | CEO | Sep 30, 2019 | Option Exercise | $3.07 | 2,256 | 6,926 | 208,984 | Oct 02, 2019, 04:18 PM |
Hadar Ilan | CFO & Country Manager | Sep 10, 2019 | Sale | $3.50 | 34,392 | 120,375 | 89,279 | Sep 11, 2019, 05:12 PM |
Hadar Ilan | CFO & Country Manager | Sep 09, 2019 | Sale | $3.50 | 9,420 | 32,991 | 123,671 | Sep 11, 2019, 05:12 PM |
KAZANCHYAN ANNA | Director | Aug 26, 2019 | Sale | $3.27 | 7,049 | 23,050 | 37,498 | Aug 28, 2019, 04:36 PM |
Hirsch Stanley | Director | Aug 13, 2019 | Option Exercise | $0.62 | 60,000 | 37,200 | 60,000 | Aug 14, 2019, 02:59 PM |
KAZANCHYAN ANNA | Director | Jul 15, 2019 | Sale | $2.31 | 808 | 1,866 | 44,547 | Jul 17, 2019, 04:40 PM |
Harsch Mutya | CLO and General Counsel | Jul 01, 2019 | Sale | $2.35 | 639 | 1,502 | 51,969 | Jul 03, 2019, 04:28 PM |
Domzalski David | CEO | Jul 01, 2019 | Sale | $2.35 | 3,355 | 7,884 | 211,240 | Jul 03, 2019, 04:27 PM |
Stuart Iain | Chief Scientific Officer | Jul 01, 2019 | Sale | $2.35 | 951 | 2,235 | 63,524 | Jul 03, 2019, 04:26 PM |
KAZANCHYAN ANNA | Director | May 20, 2019 | Sale | $2.61 | 10,600 | 27,666 | 45,355 | May 20, 2019, 06:35 PM |
Harsch Mutya | CLO and General Counsel | Apr 01, 2019 | Sale | $3.75 | 2,519 | 9,446 | 52,608 | Apr 03, 2019, 04:42 PM |
Domzalski David | CEO | Apr 01, 2019 | Sale | $3.75 | 5,096 | 19,110 | 214,595 | Apr 03, 2019, 04:40 PM |
Stuart Iain | Chief Scientific Officer | Apr 01, 2019 | Sale | $3.75 | 1,696 | 6,360 | 64,475 | Apr 03, 2019, 12:00 AM |
Wiley Matthew T. | Chief Commercial Officer | Mar 05, 2019 | Buy | $3.76 | 13,440 | 50,534 | 63,440 | Mar 06, 2019, 04:07 PM |
Schwartz Aharon | Director | Nov 28, 2018 | Buy | $3.88 | 12,200 | 47,373 | 112,200 | Dec 06, 2018, 06:09 AM |
Schwartz Aharon | Director | Nov 27, 2018 | Buy | $3.92 | 50,000 | 195,800 | 100,000 | Dec 06, 2018, 06:09 AM |
Schwartz Aharon | Director | Nov 26, 2018 | Buy | $3.89 | 50,000 | 194,600 | 50,000 | Dec 06, 2018, 06:09 AM |
Domzalski David | CEO | Dec 03, 2018 | Sale | $4.05 | 68 | 275 | 146,409 | Dec 06, 2018, 06:06 AM |
Domzalski David | CEO | Nov 19, 2018 | Sale | $3.90 | 5,036 | 19,640 | 146,477 | Nov 20, 2018, 04:07 PM |
Howard Alvin D | VP Regulatory | Nov 19, 2018 | Sale | $3.90 | 3,375 | 13,163 | 38,414 | Nov 20, 2018, 04:05 PM |
Stuart Iain | SVP R&D | Nov 08, 2018 | Sale | $4.58 | 683 | 3,128 | 33,602 | Nov 13, 2018, 06:16 AM |
Domzalski David | CEO | Nov 08, 2018 | Sale | $4.58 | 2,062 | 9,444 | 151,513 | Nov 13, 2018, 06:13 AM |
Howard Alvin D | VP Regulatory | Oct 01, 2018 | Sale | $5.81 | 234 | 1,360 | 41,789 | Oct 02, 2018, 05:22 PM |
Elliott Russell P. | VP Drug Development | Oct 01, 2018 | Sale | $5.81 | 142 | 825 | 12,442 | Oct 02, 2018, 05:20 PM |
Domzalski David | CEO | Oct 01, 2018 | Sale | $5.81 | 601 | 3,492 | 153,575 | Oct 02, 2018, 05:18 PM |
Domzalski David | CEO | Sep 04, 2018 | Sale | $5.67 | 67 | 380 | 154,176 | Sep 06, 2018, 04:05 PM |
Domzalski David | CEO | Aug 08, 2018 | Sale | $5.68 | 8,238 | 46,792 | 154,243 | Aug 09, 2018, 04:07 PM |
Stuart Iain | SVP R&D | Aug 08, 2018 | Sale | $5.68 | 2,715 | 15,421 | 34,285 | Aug 09, 2018, 04:05 PM |
Domzalski David | CEO | Jul 02, 2018 | Sale | $5.10 | 602 | 3,070 | 162,481 | Jul 03, 2018, 04:09 PM |
Howard Alvin D | VP Regulatory | Jul 02, 2018 | Sale | $5.10 | 234 | 1,193 | 42,023 | Jul 03, 2018, 04:07 PM |
Elliott Russell P. | VP Drug Development | Jul 02, 2018 | Sale | $5.10 | 142 | 724 | 12,584 | Jul 03, 2018, 04:05 PM |
Domzalski David | CEO | Jun 01, 2018 | Sale | $5.26 | 67 | 352 | 163,083 | Jun 04, 2018, 02:20 PM |
Hirsch Stanley | Director | May 13, 2018 | Sale | $5.09 | 6,164 | 31,369 | 6,508 | May 31, 2018, 04:51 PM |
Hirsch Stanley | Director | May 13, 2018 | Option Exercise | $5.04 | 6,224 | 31,369 | 12,672 | May 31, 2018, 04:51 PM |
Howard Alvin D | VP Regulatory | Apr 02, 2018 | Sale | $5.08 | 234 | 1,189 | 42,257 | Apr 04, 2018, 12:32 PM |
Elliott Russell P. | VP Drug Development | Apr 02, 2018 | Sale | $5.08 | 142 | 721 | 12,726 | Apr 04, 2018, 12:30 PM |
Domzalski David | CEO | Apr 02, 2018 | Sale | $5.08 | 602 | 3,058 | 139,754 | Apr 04, 2018, 12:28 PM |
Elliott Russell P. | VP Drug Development | Mar 02, 2018 | Sale | $6.14 | 817 | 5,016 | 12,868 | Mar 06, 2018, 11:50 AM |
Domzalski David | CEO | Mar 01, 2018 | Sale | $5.95 | 66 | 393 | 140,356 | Mar 05, 2018, 11:37 AM |
Elliott Russell P. | VP Drug Development | Jan 02, 2018 | Option Exercise | $5.98 | 555 | 3,319 | 4,935 | Jan 24, 2018, 08:26 PM |
Domzalski David | CEO | Jan 02, 2018 | Option Exercise | $5.98 | 2,397 | 14,334 | 140,422 | Jan 24, 2018, 08:24 PM |
Howard Alvin D | VP Regulatory | Jan 02, 2018 | Option Exercise | $5.98 | 924 | 5,526 | 34,991 | Jan 24, 2018, 08:22 PM |
Eini Meir | Observer to the Board | Jan 09, 2018 | Sale | $6.10 | 5,000 | 30,520 | 2,727,781 | Jan 18, 2018, 05:10 PM |
Eini Meir | Observer to the Board | Jan 08, 2018 | Sale | $6.17 | 5,000 | 30,850 | 2,732,781 | Jan 18, 2018, 05:10 PM |
Eini Meir | Observer to the Board | Jan 05, 2018 | Sale | $6.58 | 5,000 | 32,882 | 2,737,781 | Jan 18, 2018, 05:10 PM |
Eini Meir | Observer to the Board | Jan 04, 2018 | Sale | $6.68 | 5,000 | 33,411 | 2,742,781 | Jan 18, 2018, 05:10 PM |
Eini Meir | Observer to the Board | Jan 03, 2018 | Sale | $6.26 | 5,000 | 31,311 | 2,747,781 | Jan 18, 2018, 05:10 PM |
Eini Meir | Observer to the Board | Jan 11, 2018 | Sale | $6.33 | 5,000 | 31,658 | 2,717,781 | Jan 18, 2018, 05:10 PM |
Eini Meir | Observer to the Board | Jan 02, 2018 | Sale | $6.18 | 5,000 | 30,903 | 2,752,781 | Jan 18, 2018, 05:10 PM |
Eini Meir | Observer to the Board | Jan 10, 2018 | Sale | $6.05 | 5,000 | 30,227 | 2,722,781 | Jan 18, 2018, 05:10 PM |
Owner | Relationship | Date | Value($) |
Domzalski David | CEO | 03/02/2020 | 12,598 |
Wiley Matthew T. | Chief Commercial Officer | 03/02/2020 | 5,336 |
Harsch Mutya | CLO and General Counsel | 03/02/2020 | 4,715 |
Wiley Matthew T. | Chief Commercial Officer | 12/31/2019 | 8,200 |
Stuart Iain | Chief Scientific Officer | 12/31/2019 | 1,686 |
Harsch Mutya | CLO and General Counsel | 12/31/2019 | 2,027 |
Domzalski David | CEO | 12/31/2019 | 9,023 |
Domzalski David | CEO | 11/29/2019 | 21,249 |
Wiley Matthew T. | Chief Commercial Officer | 11/29/2019 | 21,249 |
Harsch Mutya | CLO and General Counsel | 11/29/2019 | 9,249 |
Hirsch Stanley | Director | 11/04/2019 | 20,150 |
Hirsch Stanley | Director | 10/15/2019 | 55,800 |
Stuart Iain | Chief Scientific Officer | 09/30/2019 | 2,066 |
Harsch Mutya | CLO and General Counsel | 09/30/2019 | 1,421 |
Domzalski David | CEO | 09/30/2019 | 6,926 |
Hadar Ilan | CFO & Country Manager | 09/10/2019 | 120,375 |
Hadar Ilan | CFO & Country Manager | 09/09/2019 | 32,991 |
KAZANCHYAN ANNA | Director | 08/26/2019 | 23,050 |
Hirsch Stanley | Director | 08/13/2019 | 37,200 |
KAZANCHYAN ANNA | Director | 07/15/2019 | 1,866 |
Harsch Mutya | CLO and General Counsel | 07/01/2019 | 1,502 |
Domzalski David | CEO | 07/01/2019 | 7,884 |
Stuart Iain | Chief Scientific Officer | 07/01/2019 | 2,235 |
KAZANCHYAN ANNA | Director | 05/20/2019 | 27,666 |
Harsch Mutya | CLO and General Counsel | 04/01/2019 | 9,446 |
Domzalski David | CEO | 04/01/2019 | 19,110 |
Stuart Iain | Chief Scientific Officer | 04/01/2019 | 6,360 |
Wiley Matthew T. | Chief Commercial Officer | 03/05/2019 | 50,534 |
Schwartz Aharon | Director | 11/28/2018 | 47,373 |
Schwartz Aharon | Director | 11/27/2018 | 195,800 |
Schwartz Aharon | Director | 11/26/2018 | 194,600 |
Domzalski David | CEO | 12/03/2018 | 275 |
Domzalski David | CEO | 11/19/2018 | 19,640 |
Howard Alvin D | VP Regulatory | 11/19/2018 | 13,163 |
Stuart Iain | SVP R&D | 11/08/2018 | 3,128 |
Domzalski David | CEO | 11/08/2018 | 9,444 |
Howard Alvin D | VP Regulatory | 10/01/2018 | 1,360 |
Elliott Russell P. | VP Drug Development | 10/01/2018 | 825 |
Domzalski David | CEO | 10/01/2018 | 3,492 |
Domzalski David | CEO | 09/04/2018 | 380 |
Domzalski David | CEO | 08/08/2018 | 46,792 |
Stuart Iain | SVP R&D | 08/08/2018 | 15,421 |
Domzalski David | CEO | 07/02/2018 | 3,070 |
Howard Alvin D | VP Regulatory | 07/02/2018 | 1,193 |
Elliott Russell P. | VP Drug Development | 07/02/2018 | 724 |
Domzalski David | CEO | 06/01/2018 | 352 |
Hirsch Stanley | Director | 05/13/2018 | 31,369 |
Hirsch Stanley | Director | 05/13/2018 | 31,369 |
Howard Alvin D | VP Regulatory | 04/02/2018 | 1,189 |
Elliott Russell P. | VP Drug Development | 04/02/2018 | 721 |
Domzalski David | CEO | 04/02/2018 | 3,058 |
Elliott Russell P. | VP Drug Development | 03/02/2018 | 5,016 |
Domzalski David | CEO | 03/01/2018 | 393 |
Elliott Russell P. | VP Drug Development | 01/02/2018 | 3,319 |
Domzalski David | CEO | 01/02/2018 | 14,334 |
Howard Alvin D | VP Regulatory | 01/02/2018 | 5,526 |
Eini Meir | Observer to the Board | 01/09/2018 | 30,520 |
Eini Meir | Observer to the Board | 01/08/2018 | 30,850 |
Eini Meir | Observer to the Board | 01/05/2018 | 32,882 |
Eini Meir | Observer to the Board | 01/04/2018 | 33,411 |
Eini Meir | Observer to the Board | 01/03/2018 | 31,311 |
Eini Meir | Observer to the Board | 01/11/2018 | 31,658 |
Eini Meir | Observer to the Board | 01/02/2018 | 30,903 |
Eini Meir | Observer to the Board | 01/10/2018 | 30,227 |